BridgeBio is demonstrably boosted its development of an new solution for amyloid heart disease, employing the investigational drug. Initial patient results indicates promising improvements for patients affected by a https://biotech614502.izrablog.com/42481796/bridgebio-progresses-cardiac-amyloidosis-therapy-using-the-drug